Radiotherapy for newly diagnosed primary central nervous system lymphoma: role and perspective.
Fiche publication
Date publication
juin 2023
Journal
Reports of practical oncology and radiotherapy : journal of Greatpoland Cancer Center in Poznan and Polish Society of Radiation Oncology
Auteurs
Membres identifiés du Cancéropôle Est :
Pr ANTONI Delphine
Tous les auteurs :
Thomas A, Houillier C, Antoni D, Hoang-Xuan K, Soussain C, Jacob J, Feuvret L
Lien Pubmed
Résumé
Whole brain radiotherapy (WBRT) has long been a key treatment of newly diagnosed primary central nervous system lymphoma (PCNSL). In the 1990s, the addition of high dose Methotrexate-based induction chemotherapy (HD MTX-based CT) has enabled a drastic improvement in PCNSL patients outcome. However, combined treatment has led to radiation-induced delayed neurotoxicity, especially in older patients. Alternative treatment strategies have been assessed to improve the efficacy and neurotoxicity ratio. Nowadays, in the elderly patients WBRT is widely omitted or deferred, and in younger patients WBRT is challenged by high dose chemotherapy with autologous stem cell transplant (HCT-ASCT) for consolidation treatment after HD MTX-based CT. In this setting, this review is addressed to clinicians with the aim to summarize the role of WBRT in the treatment of newly diagnosed PCNSL and its perspectives.
Mots clés
central nervous system, chemotherapy, lymphoma, neurotoxicity, radiotherapy
Référence
Rep Pract Oncol Radiother. 2023 06 26;28(2):271-285